[CAS NO. 252188-71-9] Ceftobiprole medocaril sodium

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [252188-71-9]

Catalog

HY-106574A

Brand

MCE

CAS

252188-71-9

DESCRIPTION [252188-71-9]

Overview

MDL	-
Molecular Weight	712.64
Molecular Formula	C26H25N8NaO11S2
SMILES	O=C(C(N(C1=O)[C@@](SC2)([H])[C@@H]1NC(/C(C3=NSC(N)=N3)=N\O)=O)=C2/C=C(CCN4[C@@](CC5)([H])CN5C(OCC(OC6=O)=C(O6)C)=O)/C4=O)O[Na]

For research use only. We do not sell to patients.

Summary

Ceftobiprole medocaril (BAL5788) sodium is the parenteral proagent of Ceftobiprole ( HY-112579 ). Ceftobiprole is a parenteral pyrrolidinone cephalosporin. Ceftobiprole is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci. Ceftobiprole also inhibits gram-positive and gram-negative pathogens ^[1] ^[2] .

In Vivo

Ceftobiprole medocaril (s.c.; 3 × q12h; total daily doses of BAL9141 equivalents, 2.1, 4.2, or 8.4 mg/kg) causes ten-day cumulative survival rates ranged from 57 to 100% for female Swiss albino mice (body weight, 20 to 22 g) infected Pen ^r Cro ^s Ctx ^s strain P-15986 ^[1] .
Ceftobiprole medocaril (10, 40, 160 mg/kg; single dose; sc) has T _1/2 s from 20 min to 31 min, as the dose rose from 40 mg/kg to 160 mg/kg. The AUC/dose values for the escalating single doses ranges from 0.585 to 1.33, and the C _max /dose values decreases from 1.08 to 0.90 in neutropenic thigh-infected mice ^[2] .

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00228982	Basilea Pharmaceutica	Skin Diseases, Infectious\|Skin Diseases, Bacterial\|Staphylococcal Skin Infections	October 2004	Phase 3
NCT00210899	Basilea Pharmaceutica	Skin Diseases, Infectious\|Skin Diseases, Bacterial\|Staphylococcal Skin Infections	September 2005	Phase 3
NCT03317093	Centre Hospitalier Universitaire Dijon	Inflamed Meninges\|Suspected Meningitis\|Ventriculitis	March 29, 2018	Phase 2
NCT00505258	Basilea Pharmaceutica	Bacteremia		Phase 2
NCT03439124	Basilea Pharmaceutica	Community-acquired Pneumonia (CAP)\|Hospital-acquired Pneumonia (HAP)	November 27, 2017	Phase 3
NCT03138733	Basilea Pharmaceutica\|Department of Health and Human Services	Staphylococcus Aureus Bacteremia	August 26, 2018	Phase 3
NCT05856227	Basilea Pharmaceutica	Neonatal Sepsis	August 2023	Phase 3
NCT03137173	Basilea Pharmaceutica	Acute Bacterial Skin and Skin Structure Infections	February 19, 2018	Phase 3
NCT00326287	Basilea Pharmaceutica	Pneumonia	June 2006	Phase 3
NCT04170309	Advanz Pharma\|AMS Advanced Medical Services GmbH\|APCER Life Sciences	Renal Insufficiency\|Hepatic Insufficiency\|Immunosuppression	March 30, 2020
NCT02527681	Basilea Pharmaceutica	Bacterial Infections	November 22, 2016	Phase 1
NCT00529282	Basilea Pharmaceutica	Fever\|Neutropenia\|Gram-positive Bacterial Infections\|Pseudomonas Infection	October 2007	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

DMSO : 250 mg/mL ( 350.81 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.4032 mL	7.0162 mL	14.0323 mL
5 mM	0.2806 mL	1.4032 mL	2.8065 mL
10 mM	0.1403 mL	0.7016 mL	1.4032 mL

* Please refer to the solubility information to select the appropriate solvent.